EWHA WOMANS UNIVERSITY MOKDONG HOSPITAL

The Myeloma Center provides the optimal treatment environment for patients with multiple myeloma, which has seen a rapid increase in recent years, especially among the elderly, and delivers top-quality, personalized medical services using the latest therapeutic methods. Multiple myeloma is a form of blood cancer in which plasma cells in the bone marrow, which is responsible for producing antibodies, become malignant and cause various complications. The disease is typically first diagnosed when patients show such symptoms as anemia, bone lesions, or infections due to compromised immunity. Often, elderly patients are diagnosed with multiple myelomas while being treated for unexplained anemia or back pain. In some cases, patients visit the hospital because of symptoms like declining renal function or nerve damage. Before the 2000s, treatment options for multiple myeloma were very limited, and patients typically survived only one to two years. However, continuous research and development of new medicines since the 2000s has resulted in the creation of various anticancer agents, leading to a growing number of patients who are now surviving for over a decade. Among blood cancers, multiple myeloma remains among the diseases that continue to benefit from ongoing medical advancements. The diagnosis and treatment of multiple myeloma is undergoing a period of dramatic change, such as the recent rapid increase in new treatment medicines and the introduction of CAR-T cell therapy. Managing this disease now requires the expertise of specialists in diverse fields. Furthermore, because most such patients are elderly and require long-term care, support from both medical staff and family members is indispensable. The Myeloma Center of Ewha Womans University Blood Cancer Hospital is dedicated to improving patient treatment outcomes by applying the latest treatment methods to cases of multiple myeloma. The center is also working continuously to increase opportunities for patients to access innovative medicines at an early stage, even those that have not yet been introduced in Korea, by participating in clinical trials conducted by both domestic and global pharmaceutical companies. Accordingly, the Myeloma Center is committed to providing professional, trustworthy medical services to patients and their families, and to curing patients and enabling them to enjoy a better quality of life by combining cutting-edge therapies with friendly care.